ArticleBlood cancer journal2025

Real world outcomes with the use of Inotuzumab Ozogamicin in relapsed/refractory B cell acute lymphoblastic leukemia.

Archita Ravindranath et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.